Difficult to Control Hypertension Clinical Trial
Official title:
A Phase 2 Double-blind, Placebo-Controlled Dose Titration Study to Evaluate the Safety and Efficacy of SQ MANP When Administered Daily for Approximately 42 Days in Subjects With Difficult to Control Hypertension/ Resistant Hypertension
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
n/a